rden2/4delta30 vaccine
Vaccineexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00089908)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rden2/4delta30 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02392325 | Phase 1 | Mar 1, 2015 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02317900 | Phase 1 | Dec 1, 2014 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02021968 | Phase 1 | Nov 1, 2013 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Vermont |
| NCT00920517 | Phase 1 | Jan 1, 2009 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00473135 | Phase 1 | May 1, 2007 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00458120 | Phase 1 | Mar 1, 2007 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00094705 | Phase 1 | Jan 1, 2005 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00089908 | Phase 1 | Sep 1, 2004 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 8 | 0 | 1 | 2004 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 8 | 8 | 1 | 2004 |
| University of Vermont | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1